VKTX - Viking Therapeutics, Inc.
| Previous Close | 4.55 |
| Open | 4.54 |
| Bid | 4.60 x 300 |
| Ask | 4.84 x 300 |
| Day's Range | 4.53 - 4.85 |
| 52 Week Range | 0.88 - 7.36 |
| Volume | 934,483 |
| Avg. Volume | 1,395,187 |
| Market Cap | 239.895M |
| Beta | 2.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.79 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.13 |
- GlobeNewswire•3 days ago
Report: Developing Opportunities within Canada Goose, Viking Therapeutics, Vector Group, Bruker, Air Transport Services Group, and Raymond James Financial — Future Expectations, Projections Moving into 2018
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Simply Wall St.•9 days ago
What Should Investors Know About Viking Therapeutics Inc’s (NASDAQ:VKTX) Future?
In December 2017, Viking Therapeutics Inc (NASDAQ:VKTX) announced its most recent earnings update, which revealed that losses became smaller relative to the prrior year’s level as a result of recentRead More...
- Motley Fool•10 days ago
Why Viking Therapeutics, Inc. Stock Cratered in March
Viking's shares finally cooled off last month, but that doesn't make them a buy.
- Zacks Small Cap Research•last month
VKTX: Data from Phase 2 Study of VK2809 in NASH in 2H18; Sufficient Cash to Fund Operations to 2020
Viking Therapeutics, Inc. (VKTX) is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. VK5211, which is being developed for acute rehabilitation following non-elective hip fracture surgery. • The company announced positive topline data from a Phase 2 trial in Nov. 2017 and we anticipate the full data set being presented at a scientific conference in the second half of 2018.
- Motley Fool•last month
Here's Why Viking Therapeutics Stock Dropped as Much as 17.3% Today
The biopharma released full-year 2017 earnings yesterday after the market closed.
- PR Newswire•2 months ago
Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today - VK5211 Phase 2 trial in hip fracture achieves primary and multiple secondary endpoints - VK2809 Phase 2 fatty liver and hypercholesterolemia study proceeding, ...
- ACCESSWIRE•2 months ago
Viking Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Viking Therapeutics, Inc. (NASDAQ: VKTX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018 at 4:30 PM Eastern ...
- PR Newswire•2 months ago
Viking Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO , March 6, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
- Investopedia•2 months ago
Penny Stocks to Watch for March 2018
Industrial metals and infrastructure plays highlight March's penny stock list, with Congress set to increase spending on roads, bridges and tunnels.
- PR Newswire•2 months ago
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018
Conference Call Scheduled for Wednesday, March 7 at 4:30 p.m. Eastern Time SAN DIEGO , Feb. 28, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Great Lakes Dredge & Dock, American Midstream Partners, LP, BioDelivery Sciences International, Viking Therapeutics, Pattern Energy Group, and Computer Programs and Systems — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Feb. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Great ...
- Simply Wall St.•2 months ago
Who Are The Major Shareholders In Viking Therapeutics Inc (NASDAQ:VKTX)?
I am going to take a deep dive into Viking Therapeutics Inc’s (NASDAQ:VKTX) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structureRead More...
- ACCESSWIRE•2 months ago
Biotricity (BTCY) Poised for Breakout with New FDA Clearance: +100% Back To Highs?
- Healthcare Stocks Ripping Higher Amid Acquisitions and Expectations for More in 2018. Cardio Monitoring Companies like IRTC and BEAT have been Great Performers as They Penetrate Huge Market - Upstart ...
- PR Newswire•2 months ago
Viking Therapeutics to Present at 2018 BIO CEO & Investor Conference
SAN DIEGO , Feb. 7, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
- PR Newswire•2 months ago
Viking Therapeutics Announces Closing of Public Offering of Common Stock
Viking currently intends to use the net proceeds from the offering for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development, working capital and general corporate purposes. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
SmarterAnalyst•3 months agoViking Therapeutics Inc Now Has Cash Runway to Hit Multiple Catalysts Through 2020; Jason McCarthy Chimes in
On a day like today, when the entire stock market is under pressure, you must have done something right to see your stock jump more than 15%. What is magnetizing investors to invest in Viking Therapeutics Inc (NASDAQ:VKTX) today? The pricing of a public offering- as Viking ties up an equity financing, it is pricing its public offering of common stock to bring $55 million to its table.
- PR Newswire•3 months ago
Viking Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock
SAN DIEGO, Feb. 2, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its public offering of 11,000,000 shares of its common stock at a price to the public of $5.00 per share. Viking currently intends to use the net proceeds from the offering for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development, working capital and general corporate purposes. William Blair & Company, L.L.C. is acting as sole book-running manager for the offering and Maxim Group LLC and Roth Capital Partners are acting as co-managers for the offering.
- PR Newswire•3 months ago
Viking Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, Feb. 1, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Viking also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares to be sold in the offering are to be sold by Viking.
- Simply Wall St.•3 months ago
Should You Be Concerned About Viking Therapeutics Inc’s (NASDAQ:VKTX) Risks?
If you are a shareholder in Viking Therapeutics Inc’s (NASDAQ:VKTX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
- TheStreet.com•3 months ago
Biotech Viking Therapeutics Could Double From Here -- But Not Without Risk
Interest and volume in the stock picked up in September and continues to build.
- Zacks Small Cap Research•3 months ago
VKTX: Positive Results for MGL-3196 Increases Our Confidence for Success of VK2809 Phase 2 Trial
Viking Therapeutics, Inc. (VKTX) is currently testing VK2809, the company’s thyroid hormone receptor beta (TRβ) agonist, in a Phase 2 clinical trial in patients with hypercholesterolemia and fatty liver disease. The company is enrolling patients with elevated cholesterol and fatty liver disease, as assessed by liver fat content ≥ 8% by MRI-PDFF. The primary endpoint will assess changes in LDL cholesterol following 12 weeks of treatment, with exploratory endpoints evaluating changes in liver fat content, inflammatory markers, and histological changes.
- PR Newswire•4 months ago
Viking Therapeutics to Present at Biotech Showcase 2018
SAN DIEGO , Jan. 2, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
- Simply Wall St.•4 months ago
What Should We Expect From Viking Therapeutics Inc’s (NASDAQ:VKTX) Earnings Over The Next Few Years?
Viking Therapeutics Inc’s (NASDAQ:VKTX) released its most recent earnings update in September 2017, which revealed that losses became smaller relative to the prrior year’s level – great news for investorsRead More...
- PR Newswire•4 months ago
Viking Therapeutics Announces Closing of Public Offering of Common Stock
Viking currently intends to use the net proceeds from the offering for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development, working capital and general corporate purposes. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
InvestorPlace•4 months ago5 Cheap Biotech Stocks to Snag on the Bounce
One sector group in particular looks ready to profit from the upward drift are the biotech stocks, which have been on the decline in recent weeks as investors focus on Big Tech stocks and more recently on high-tax issues most likely to benefit from the GOP’s corporate tax cut plans.
